지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2014.1
- 수록면
- 1,576 - 1,583 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Teriparatide markedly increases bone formation and strength, while reducingthe incidence of new-onset osteoporotic vertebral compression fractures (OVCFs). In some countries, expenses for teriparatide use are covered by medical insurance for up to 6 months; however, the national medical insurance of the authors’country does not cover these expenses. This retrospective cohort study comparedthe therapeutic effects of teriparatide on the initial onset of a new OVCF aftertreatment of osteoporosis and/or related OVCFs with regard to therapeutic durations of longer than 3 months (LT3M) or shorter than 3 months (ST3M). Materialsand Methods: From May 2007 to February 2012, 404 patients who were prescribed and administered teriparatide and who could be followed-up for longer than 12 months were enrolled. They were divided into two groups depending on teriparatide duration: LT3M (n=132) and ST3M (n=272). Results: The group with the teriparatide duration of LT3M showed significantly less development of an initialOVCF within 1 year (p=0.004, chi-square). Duration of teriparatide use, body mass index, pre-teriparatide lowest spinal bone mineral density, and severity of osteoporosissignificantly affected multiple regression analysis results (p<0.05). Survivalanalysis of first new-onset OVCFs demonstrated a significantly better survivalrate for the LT3M group (log rank, p=0.005). Also, the ST3M group showed a higher odds ratio of 54.00 for development of an initial OVCF during follow-up than the LT3M group (Mantel-Haenzel common odds ratio, p=0.006). Conclusion: At least one cyclic teriparatide administration is recommended to provide a protectiveeffect against the initial onset of a new OVCF for up to one year after therapy.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Binkley N / 2005 / Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures / Osteoporos Int 16 : 1513 ~ 1518
Black DM / 1996 / Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group / Lance
Cosman F / 2005 / Daily and cyclic parathyroid hormone in women receiving alendronate / N Engl J Med 353 : 566 ~ 575
Dempster DW / 2001 / Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study / J Bone
Ettinger B / 1999 / Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. M
Black DM / 1996 / Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group / Lance
Cosman F / 2005 / Daily and cyclic parathyroid hormone in women receiving alendronate / N Engl J Med 353 : 566 ~ 575
Dempster DW / 2001 / Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study / J Bone
Ettinger B / 1999 / Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. M
이 논문의 저자 정보
최근 본 자료
댓글(0)
0